Axsome Therapeutics Inc Cash Flow Conversion Efficiency
Axsome Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has a cash flow conversion efficiency ratio of -0.396x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.95 Million) by net assets ($83.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AXSM market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Axsome Therapeutics Inc (2013–2025)
Cash flow conversion efficiency of Axsome Therapeutics Inc from 2013 to 2025. This chart illustrates how Axsome Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AXSM share price today for real-time trading data and today's change.
Axsome Therapeutics Inc Cash Flow Conversion Ratio Explained
Axsome Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Axsome Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axsome Therapeutics Inc ranked by their cash flow conversion efficiency. Review AXSM free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Phoenix Mills Limited
NSE:PHOENIXLTD
|
0.086x |
|
Ryman Hospitality Properties Inc
NYSE:RHP
|
0.193x |
|
PACS Group, Inc.
NYSE:PACS
|
0.333x |
|
Fibra UNO
MX:FUNO11
|
0.011x |
|
National Fuel Gas Company
NYSE:NFG
|
0.096x |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
-0.142x |
|
VeriSilicon Microelectronics Shanghai Co Ltd
SHG:688521
|
-0.007x |
|
Mytilineos S.A
AT:MYTIL
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Axsome Therapeutics Inc from 2013 to 2025. Also see Axsome Therapeutics Inc total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $88.30 Million | $-93.41 Million | -1.058x | +53.03% |
| 2024-12-31 | $57.02 Million | $-128.41 Million | -2.252x | -196.47% |
| 2023-12-31 | $190.98 Million | $-145.08 Million | -0.760x | +28.57% |
| 2022-12-31 | $109.56 Million | $-116.51 Million | -1.063x | +84.64% |
| 2021-12-31 | $15.63 Million | $-108.23 Million | -6.924x | -904.27% |
| 2020-12-31 | $113.79 Million | $-78.46 Million | -0.689x | -165.71% |
| 2019-12-31 | $178.72 Million | $-46.38 Million | -0.259x | +99.19% |
| 2018-12-31 | $937.92K | $-30.05 Million | -32.043x | -1923.55% |
| 2017-12-31 | $16.72 Million | $-26.47 Million | -1.583x | -60.51% |
| 2016-12-31 | $21.57 Million | $-21.28 Million | -0.987x | -515.94% |
| 2015-12-31 | $46.44 Million | $-7.44 Million | -0.160x | -111.16% |
| 2014-12-31 | $-3.20 Million | $-4.60 Million | 1.435x | +78.43% |
| 2013-12-31 | $-2.03 Million | $-1.63 Million | 0.804x | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more